Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?

Immunotherapies have been incorporated in the treatment strategy of advanced non-small cell lung cancer (NSCLC), with worldwide pembrolizumab approval as upfront single agent for tumors with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of ≥50%, and recently with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approvals of pembrolizumab in combination with chemotherapy for non-squamous lung cancer, irrespective of PD-L1 status.